Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit
At the expanded cohort, part 2 of the study, subjects must have one of the following:
Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy
Diffuse large B-cell lymphoma
Age 18 years or older
You may not be if
Candidate for potentially curative therapies in the opinion of the investigator
Chronic lymphocytic leukemia
Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma
Clareo Health | Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
